28-30 April Liverpool
![]() |
![]() |
![]() |
![]() |
1-EP | Characterization of Acute Promyelocytic Leukaemia: follow up study at a tertiary care center | Maymoona Suhail | ![]() |
![]() |
|||
2-EP | c-MYC gene expression in hematological malignancies: Diagnostic and prognostic value | Ifeyinwa Okafor | ![]() |
![]() |
|||
3-EP | RELATIONSHIP OF ENDOGENOUS CYTOKINES TNF, TGF1 IN ACUTE MYELOBLASTIC LEUKEMIA WITH SEVERITY OF CYTOPENIA | Vira Barilka | ![]() |
![]() |
|||
4-EP | How Does Chemotherapy Affects Elderly AML Patients? | Manal Aboelmagd | ![]() |
![]() |
|||
5-PO | Physical Isolation of Tumour Associated ctDNA Fragments for Novel AML Liquid Biopsy | Maisie Spurling | ![]() |
![]() |
|||
5-EP | Acute Myeloid Leukaemia in Adolescents and Young Adults: A Distinct Entity? | Mohamed H. Omer | ![]() |
![]() |
|||
8-EP | Real-World Data on Venetoclax-Based Non-Intensive Chemotherapy for AML in an Elderly, Rural Population | Martha Vickers | ![]() |
![]() |
|||
9-EP | Precise FISH panels guided by population prevalence may assist pragmatic diagnosis of Ph-like ALL | Jane Thompson | ![]() |
![]() |
|||
10-EP | Identifying low risk AML patients on Azacitidine and Venetoclax that do not require inpatient monitoring | Verigou Eleni-Anna | ![]() |
![]() |
|||
11-EP | An Observational Study of AML Patients Treated with Vyxeos Chemotherapy - A Single Centre | Matthew Duffy | ![]() |
![]() |
|||
12-EP | Long Term Outcomes of Stem-Cell-Transplant in Older Patients with AML treated with Venetoclax HMA Therapies | Kathryn Moulton | ![]() |
![]() |
|||
13-EP | A Multiomic, Single-Cell Measurable Residual Disease (SCMRD) Assay For Phasing DNA Mutations And Surface Immunophenotypes | Matteo Cattaneo | ![]() |
![]() |
|||
14-EP | Morbidity and Mortality Outcomes in Acute Myeloid Leukaemia Patients Treated with Venetoclax and Azacitidine Chemotherapy | Francesca Leonforte | ![]() |
![]() |
|||
15-EP | Palliative haematology clinic for patients with Bone Marrow failure syndromes and Acute Myeloid Leukaemia. | Jayne Osborne | ![]() |
![]() |
|||
16-EP | Review of the Acute Leukaemia Services at a District General Hospital | Ethan Wong | ![]() |
![]() |
|||
17-EP | Real-world Experience of Venetoclax with Azacitidine or Cytarabine for the Treatment of Acute Myeloid Leukaemia | Emily Sutherland | ![]() |
![]() |
|||
18-EP | High Survival Rate in Haematology Patients Admitted to ICU in a Tertiary Referral Centre | Hannah Sadler | ![]() |
![]() |
|||
18-PO | Variants in Development of Pure Red Cell Aplasia & Treatment Approaches:Single Centre Study in UK | Sukanya Gogoi | ![]() |
![]() |
|||
19-PO | Venetoclax Azacitadine as First Line Treatment for AML Real-World Data from a Multi-Centre Study | Holly Gilbert | ![]() |
![]() |
|||
19-EP | Real-world Outcomes for Patients with Acute Myeloid Leukaemia treated with Venetoclax-Azacytidine in North of England | Yashashree Gupta | ![]() |
![]() |
|||
20-EP | IKZF1 Deletion in Acute Lymphoblastic Leukemia: a Single-Center Experience in Thailand | Suchada Sommaluan | ![]() |
![]() |
|||
20-PO | Elucidating the S100A4-Mediated Mechanisms Promoting AML Blast Proliferation and Survival | Rehab Alanazi | ![]() |
![]() |
|||
22-EP | Targeting NOX2 Overexpression in Acute Myeloid Leukaemia using In Vitro Models | Sian Rizzo | ![]() |
![]() |
|||
22-PO | The Benefit of Nurse Led Group End of Treatment Summary Sessions for Patients. | Nicola Goffinet | ![]() |
![]() |
|||
23-EP | Phase 3b Design: Comparing Treatment Preference Between Oral Decitabine/Cedazuridine and Azacitidine in Patients with Leukaemias | Hemal Parmar | ![]() |
![]() |
|||
24-EP | Outcomes of Venetoclax based therapy for AML Patients - A UK DGH Real World Experience | Olamide BELLO | ![]() |
![]() |
|||
25-EP | How Much Is Too Much? Audit of Routine Biochemistry Requests For AML Inpatients on Chemotherapy | Tioluwanimi Ojeola | ![]() |
![]() |
|||
26-EP | Management of acute leukaemia and pregnancy outcomes in patients with current or previous leukaemia | David Allsup | ![]() |
![]() |
|||
27-EP | Deciphering The Puzzle: Acute Leukaemias of Ambiguous Lineage | Maymoona Suhail | ![]() |
![]() |
|||
28-EP | Are CCL19 and CCL21 the keys to unlocking dendritic cell function in paediatric B-ALL? | Thomas Daley | ![]() |
![]() |
|||
30-EP | The relationship between early diagnosis and treatment of suspected secondary HLH (Haemophagocytic lymphohistiocytosis) on patient survival outcomes: a case series. | Taran Nandra | ![]() |
![]() |
|||
30-PO | Exploring perceptions in management and treatment of polycythaemia vera (PV) in the UK: PV-PINPOINT study | Mary Frances McMullin | ![]() |
![]() |
|||
31-EP | Preventative information (regarding Mucositis) given to Paediatric Patients awaiting Bone Marrow Transplants: A QI Project | Alisha Amin | ![]() |
![]() |
|||
32-EP | Referrals to a haematology day unit: has the quality improved with a new electronic system? | Sophie Ralston | ![]() |
![]() |
|||
33-PO | Rare MPIG6B Gene Mutation cause of refractory severe thrombocytopenia with myelofibrosis in adolescent. | Muzna Aquil | ![]() |
![]() |
|||
34-EP | Basics to Brilliance: A Haematology Podcast for Trainees | David Fasey | ![]() |
![]() |
|||
35-EP | Bilateral Retrobulbar Hemorrhage Causing Spontaneous Globe Subluxation in a Pediatric Patient with Factor XIII Deficiency | H Shafeeq Ahmed | ![]() |
![]() |
|||
36-PO | Application of Prognostic Scoring in Advanced Systemic Mastocytosis patients and the Impact of Novel Therapies | Priya Sriskandarajah | ![]() |
![]() |
|||
37-EP | Rosai-Dorfman Disease - a Rare Histiocytic Disorder : A Single Centre Experience Rosai-Dorfman Disease - A Rare Histiocytic Disorder : A Single Centre Experience. | Menna Shamma | ![]() |
![]() |
|||
38-EP | Adhering to best practice in a nurse led myeloproliferative clinic. | Emma Whitham | ![]() |
![]() |
|||
39-EP | Dark Web Deception: Using Laboratory Haematology to Resolve a Case of Unexplained Coagulopathy | Eleanor Sheppard | ![]() |
![]() |
|||
40-EP | Interesting case report: Acute thrombocytopaenia following an overseas renal transplant | Aoife Dervin | ![]() |
![]() |
|||
40-PO | An Audit of Corticosteroid use in ITP at Kings College Hospital NHS Trust | Rosalind Byrne | ![]() |
![]() |
|||
41-EP | Peri-operative anaemia optimisation since the Covid pandemic - a service evaluation | Amjad Hmaid | ![]() |
![]() |
|||
41-PO | Diagnosis and Treatment Patterns in European Patients with Systemic Mastocytosis | Marisa Vincenti | ![]() |
![]() |
|||
42-PO | Burden of Systemic Mastocytosis in Europe and the UK: Interim Results from PRISM Patient Survey | Marisa Vincenti | ![]() |
![]() |
|||
42-EP | Phase 3 Randomized Double-Blind Study Evaluating Selinexor, an XPO1 inhibitor, Plus Ruxolitinib in JAKi-Naïve Myelofibrosis | Jennifer OSullivan | ![]() |
![]() |
|||
43-PO | A Single-site Audit of Treatment Free Remission Identification and Monitoring in Chronic Myeloid Leukaemia Patients | Sophie Evans | ![]() |
![]() |
|||
43-EP | The Burden of Anaemia in a Primary Care Population in UK: what is Haematologys Role? | Suzanne Maynard | ![]() |
![]() |
|||
44-EP | Exceptionally High Prevalence of Iron Deficiency Anaemia in Children Residing in Rural Areas in Pakistan | Baig Aleena | ![]() |
![]() |
|||
45-EP | VAMPIRC: Venesection Audit in the Midlands for secondary Polycythaemia Investigating thRombotic Complications | Caroline Morgan | ![]() |
![]() |
|||
46-EP | Outcome of bone marrow examinations in children with isolated thrombocytopenia: Experience from LMIC | Visvalingam Arunath | ![]() |
![]() |
|||
47-EP | Hyperhaemolysis Syndrome in a Young Patient with Autoimmune Haemolytic Anaemia | Nayanathara Silpage | ![]() |
![]() |
|||
48-EP | Quality improvement and resource optimisation - Subcutaneous Immunoglobulin for secondary immunodeficiency associated with haematological disorders | Amira Chaudry | ![]() |
![]() |
|||
48-PO | Overview of Erythrocytosis and Thrombocytosis referrals within General Haematology clinics streamlining the MPN service | Xavier Peer | ![]() |
![]() |
|||
49-EP | Use of Low Dose Naltrexone and Hydroxycarbamide for Mast Cell Disorders (SM, MCAS & HaT) | Bethan Myers | ![]() |
![]() |
|||
50-EP | Investigation of Isolated Neutropenia in Childhood: Aetiology and Outcomes | Eoghan Dunlea | ![]() |
![]() |
|||
51-EP | Treatment Free Remission in CML Patients on TKIs: An Audit From A London DGH | Augustus Diaz | ![]() |
![]() |
|||
52-EP | Two years of the Genomic Haematology clinic: outcomes from a new service for South-West England | Sarah Westbury | ![]() |
![]() |
|||
54-EP | Pegylated Interferon in Myelodysplastic Syndrome/Myeloproliferative Neoplasm with Ringed Sideroblasts and Marked Thrombocytosis: Single-Centre Case Series | Mohammed Altohami | ![]() |
![]() |
|||
55-EP | Safety and Efficacy of Low Dose Pegylated Interferon (PEG-IFN) in Myeloproliferative Neoplasms: Real World Data | Mamta Garg | ![]() |
![]() |
|||
56-EP | Detection and management of iron deficiency in pregnant women who had a major obstetric haemorrhage | Adrian Choy | ![]() |
![]() |
|||
56-PO | Exploring Prognostic Factors in Myeloproliferative Neoplasms-associated Splanchnic Vein Thrombosis | Elena Torre | ![]() |
![]() |
|||
58-EP | More Than Just a Number: Impact of ITP on Psychosocial QoL in Pediatric Patients | Nazia Mumtaz | ![]() |
![]() |
|||
59-EP | Myeloproliferative Neoplasms and Thrombosis A Single Centre Retrospective Cohort Study of 111 Cases | Rupen Hargreaves | ![]() |
![]() |
|||
60-EP | Real-World, Single-Centre Experience of Pregnancy in Patients with Philadelphia Negative Myeloproliferative Neoplasms | Holly Theaker | ![]() |
![]() |
|||
61-EP | Chronic myelogenous leukemia presenting with Morel Lavallee lesion case report | Gebeyehu Tessema Azibte | ![]() |
![]() |
|||
62-EP | Use of new third-line therapy for myeloproliferative neoplasm with concurrent BCR-ABL1 translocations and JAK2-V617F mutation | Thais Ferrari Gersogamo | ![]() |
![]() |
|||
63-EP | A Real-World Patient Experiences and Quality of Life Insights Snapshot in Cold Agglutinin Disease (CAD). | Kim Summers | ![]() |
![]() |
|||
64-PO | Deaths Attributable to Transfusion-Associated Circulatory Overload: 10-year Review of Serious Hazards Of Transfusion (SHOT) Data | Oliver Firth | ![]() |
![]() |
|||
64-EP | Real-world electronic data in a haematology centre to better understand patient and care activity | Simon Stanworth | ![]() |
![]() |
|||
65-EP | Stopping TKI-therapy in CML as per the BSH guidelines, an audit from a DGH practice | Shyamala Chinnabhandara | ![]() |
![]() |
|||
65-PO | Clinical and cost effectiveness of cell salvage use in complex spinal surgery | Thomas Burton | ![]() |
![]() |
|||
66-PO | Understanding the use of CMV-seronegative blood in allogeneic-HSCT in England | Oliver Firth | ![]() |
![]() |
|||
66-EP | Refining Ph-MPN Diagnostic Pathways: Insights from an Audit of Wales Medical Genomics Service | Leila Alwadi | ![]() |
![]() |
|||
68-PO | Alloimmunisation in Sickle Cell Disease: a 3-year Retrospective Study in a Tertiary Haemoglobinopathy Treatment Centre | Kate Fletcher | ![]() |
![]() |
|||
69-EP | Patient Experience, Quality of Life and Unmet Need in UK CML Community | Andrea Preston | ![]() |
![]() |
|||
71-EP | Navigating the Storm: Adherence and Management of Polycythaemia Vera through the COVID-19 Pandemic. | Benjamin Lim | ![]() |
![]() |
|||
72-EP | PACIFICA: A Randomized, Phase 3 Study of Pacritinib Versus Physicians Choice in Patients with Myelofibrosis | Claire Harrison | ![]() |
![]() |
|||
73-PO | Large Cell Transformation of Mycosis Fungoides: Patterns of Care and Patient Outcomes | Philippa Johnstone | ![]() |
![]() |
|||
73-EP | An Audit of Use of Intravenous Immunoglobulin Therapy in Haemato-Oncology Patients | Dario Melotti | ![]() |
![]() |
|||
75-EP | Evidence of Relevant Anaemia Response in Myelofibrosis Patients with Impaired Renal Function Treated with Momelotinib | Kyaw Htin THAW | ![]() |
![]() |
|||
76-EP | Randomized, Open-Label Phase 3 Study of the Lysine-Specific Demethylase 1 Inhibitor Bomedemstat for Essential Thrombocythaemia | Rushdia Yusuf | ![]() |
![]() |
|||
76-PO | Updated Results of the Safety Run-in of the Phase 3 LOTIS-5 Trial | Yvonne Law | ![]() |
![]() |
|||
77-EP | Parathyroid hormone in plasmodium berghei infection | Kavyesh Vivek | ![]() |
![]() |
|||
79-EP | Prevalence of ABO and RhD blood group system among blood donors in Blood Centre Batticaloa. | Gauri Jayasinghe | ![]() |
![]() |
|||
80-EP | Influencing Change in Transfusion Information Technology Systems - the SCRIPT Survey and Collaborative Working Project | Victoria Tuckley | ![]() |
![]() |
|||
81-EP | Role of Therapeutic Plasma Exchange in a Child with Secondary Haemophagocytic Lymphohistiocytosis | Nayanathara Silpage | ![]() |
![]() |
|||
82-EP | Audit on the Usage of O RhD-Negative Red Cells in Emergencies in a Tertiary Hospital | Sai Lon Wann | ![]() |
![]() |
|||
83-EP | Hematological Predictors of No-Reflow in Patients Undergoing Primary PCI For STEMI. | Dr Shereen Elshazly | ![]() |
![]() |
|||
83-PO | Phase 2 Trial of Nanatinostat and Valganciclovir in Patients with EBV-Positive (EBV) Relapsed/Refractory Lymphomas (NAVAL-1) | Jacqueline Jessie | ![]() |
![]() |
|||
84-EP | DNA extracted from cultured cells as a source of survey material for Molecular Haemoglobinopathy EQA | Bashori Rahman | ![]() |
![]() |
|||
85-PO | Pirtobrutinib, a Highly Selective, Non-covalent (Reversible) BTK Inhibitor in Relapsed/Refractory Follicular Lymphoma | Huseini Kagdi | ![]() |
![]() |
|||
85-EP | Evolving Caseload of Adult Bone Marrow Biopsies in a Specialist Integrated Haematological Malignancy Diagnostic Service | jake tobin | ![]() |
![]() |
|||
86-PO | Pirtobrutinib in Prior cBTKi R/R MCL: Phase 1/2 BRUIN Study Updates including High-Risk Subgroup Analyses | Huseini Kagdi | ![]() |
![]() |
|||
86-EP | Patient Consent for Blood Transfusion: An Audit | Zoe Rose | ![]() |
![]() |
|||
87-EP | The CD47-Blocking Immune Checkpoint Inhibitor Maplirpacept Does Not Interfere with Blood Transfusion Compatibility Testing | Simon Purcell | ![]() |
![]() |
|||
88-EP | Pathology Portal: Developing a novel, interactive education portal for Transfusion Medicine | Matthew Poynton | ![]() |
![]() |
|||
88-PO | Infectious complications of bispecific antibody treatment in patients with lymphoproliferative disorders | Abigail Martin | ![]() |
![]() |
|||
90-PO | Epcoritamab GemOx in ASCT-ineligible patients with R/R DLBCL: updated results from EPCORE NHL-2 | David Lewis | ![]() |
![]() |
|||
90-EP | Insights on Erythrocyte Alloimmunization and Auto-immunization in Children from North India | Manish Raturi | ![]() |
![]() |
|||
91-EP | CDK1 Inhibitor RO-3306 Enhances BTKi Potency in Diffuse Large B-cell Lymphoma by Suppressing JAK2/STAT3 Signaling | Qiuni Chen | ![]() |
![]() |
|||
92-EP | Type 1 Cryoglobulinemic Vasculitis Associated with Marginal Zone Lymphoma Successfully Treated with Bendamustine and Rituximab | Apurwa Prasad | ![]() |
![]() |
|||
92-PO | Mitigating the risk of cytokine release syndrome: EPCORE NHL-1 DLBCL cycle 1 optimization cohort results | Kim Linton | ![]() |
![]() |
|||
93-EP | Modified DHAP Salvage Therapy for Refractory &/or Relapsed Classic Hodgkins (CHL) and Non-Hodgkins Lymphomas (NHL) | Yasmine Shaaban | ![]() |
![]() |
|||
94-EP | Identification of Plasma lncRNA for Bone Marrow Infiltration and Staging in Diffuse Large B-Cell Lymphoma | Samar Sami Elshazly Elshazly | ![]() |
![]() |
|||
95-EP | Diffuse B-large cell non-Hodgkins lymphoma(DBCL) associated with hepatitis B virus(HBV), clinical characteristics, therapy, and prognosis. | Sergey Lepkov | ![]() |
![]() |
|||
96-EP | Regional Case Series of Grey Zone Lymphoma Outcomes | Euan Haynes | ![]() |
![]() |
|||
97-PO | Awareness, Knowledge, and Acceptance of Bone Marrow Transplantation for Beta Thalassemia Major in Sri Lanka | Heroshan Hasintha Jayakadu Jayakadu mudiyanselage | ![]() |
![]() |
|||
98-EP | DAAA therapyin patients with hepatitis C associated indolent non-Hodgkin lymphomas(HCVINHL) results of prospective study | Sergey Lepkov | ![]() |
![]() |
|||
99-EP | Improving bone health in lymphoma- DGH experience | Saima Afridi | ![]() |
![]() |
|||
100-EP | Patient Initiated Follow-Up in Lymphoma: Reducing clinic appointments, cost and environmental impact | Emily Buchanan | ![]() |
![]() |
|||
101-EP | Night Sweats as a Referral Criterion for Suspected Lymphoma in the Post-COVID Era | Charlotte Dawson | ![]() |
![]() |
|||
102-EP | A Review of a District General Hospital Lymphoma Service Before and After the COVID19 Pandemic | Yen Huan Yeo | ![]() |
![]() |
|||
103-PO | Klebsiella Liver Abscesses in Paediatric Haemoglobinopathy Patients on Transfusion-Chelation Regimen | Bethany Singh | ![]() |
![]() |
|||
103-EP | Epidemiological Analysis of Hodgkins Lymphoma in a Developing Middle Eastern Country Over 18 Years | Ahmed Abdulelah | ![]() |
![]() |
|||
104-PO | Transcranial Doppler Screening of Children With Sickle Cell Disease in the HOPE Kids 2 Trial | Jack Jung | ![]() |
![]() |
|||
104-EP | Epidemiological Analysis of Non-Hodgkins Lymphoma in a Developing Middle Eastern Country Over 18 Years | Ahmed Abdulelah | ![]() |
![]() |
|||
105-PO | Over 4 Years of Safety and Efficacy With Voxelotor in Patients with Sickle Cell Disease | Jack Jung | ![]() |
![]() |
|||
105-EP | A multiplexed fluorescent immunohistochemical analysis of CXCR4/CXCL12 axis in de novo and CNS B-cell lymphoma | TAN JIAO JIE CHERIE | ![]() |
![]() |
|||
106-EP | A Child with Sporadic Burkitt lymphoma presenting as acute flaccid paralysis and capillary leak syndrome | Visvalingam Arunath | ![]() |
![]() |
|||
107-EP | Axicabtagene Ciloleucel Real-World Manufacturing Experience in the United Kingdom | Vaishali Dulobdas | ![]() |
![]() |
|||
108-PO | Real-World Patient Awareness Around Emerging Gene Therapies: Implications for Barriers to Access. | Kim Summers | ![]() |
![]() |
|||
109-PO | Serum Soluble VCAM-1 is Not Associated with Severity of SCD in Adult Ghanaian Patients | Willliam Ghunney | ![]() |
![]() |
|||
109-EP | Single Centre Experience of Personalised Stratified Follow-Up for Patients with Lymphoma Treated with Curative Intent | Sapna Ladani | ![]() |
![]() |
|||
110-EP | Diffuse B-large cell non-Hodgkins lymphoma associated with hepatitis C (HCVDBCL): clinic and therapy results | Sergey Lepkov | ![]() |
![]() |
|||
111-EP | Pilot for Speeding up the Diagnosis of Lymphadenopathies | Gillian Flynn | ![]() |
![]() |
|||
112-EP | Elderly Patient With Hematological and Neurological Manifestations of Undetermined Origin: A Diagnostic Dilemma of Pernicious Anemia | Anas Ibraheem | ![]() |
![]() |
|||
112-PO | Efanesoctocog Alfa Prophylaxis Outcomes in European Patients From the XTEND-1 Trial | Mark Smith | ![]() |
![]() |
|||
113-EP | Preoperative Transfusion in Patients with Sickle Cell Disease: Systematic Review & Meta-analysis | Khalid Elhag Mohamed Ahmed Ahmed | ![]() |
![]() |
|||
114-EP | Causal relations between autoimmune diseases and aplastic anemia: a bidirectional two-sample Mendelian randomization study | Qiuni Chen | ![]() |
![]() |
|||
114-PO | Overview of the Effect of Anticoagulants on Heavy Menstrual Bleeding in Women with Thrombosis | Rawya Hussein | ![]() |
![]() |
|||
115-EP | Severe B12 Deficiency Mimicking HELLP Syndrome; A Case Report | Aneesa Rameh | ![]() |
![]() |
|||
116-EP | Use of Conventional Transfusion Thresholds Contribute to Iron Overload in Patients with Sickle Cell Disease | Niravkumar Brahmbhatt | ![]() |
![]() |
|||
118-EP | METHEMOGLOBINEMIA A CASE REPORT | Zahra Hasan | ![]() |
![]() |
|||
119-EP | Design and Implementation of sickle cell disease electronic registry in limited resources setting in Nigeria | Muhammad Aminu Idris | ![]() |
![]() |
|||
120-EP | Minimizing Alloimmunization: Rethinking Blood Transfusions in Acute Chest Syndrome Management | Melissa Friday | ![]() |
![]() |
|||
121-EP | Dapsone induced haemolytic anaemia and methemoglobinemia in a paediatric case study | EMILY BROAD | ![]() |
![]() |
|||
122-EP | Between The Extremes .. A Case report of polycythemia Vera post autoimmune haemolytic anemia | Asmaa Mohsen | ![]() |
![]() |
|||
123-EP | Management of obstetric patients with sickle cell disease a case series | Ismini Panayotidis | ![]() |
![]() |
|||
124-EP | Is Umbilical Cord Blood a Better Treatment for Treating Paediatric Patient with Sickle Cell Disease | Ebehiremen Ebhodaghe | ![]() |
![]() |
|||
125-EP | Treatment of Autoimmune Hemolytic Anemia in Beta Thalassemia Major | Gulab Fatima Rani | ![]() |
![]() |
|||
126-EP | Pharmacological Intervention for Pain Management in Paediatric Sickle cell Anaemia Patient: A Network Meta-Analysis | Nabiel Muhammad Haykal | ![]() |
![]() |
|||
128-EP | Evaluation of Some Haemostatic Parameters in Management of HBV Infection Treatment Outcome in Asaba Nigeria. | Sylvia Obu | ![]() |
![]() |
|||
132-EP | An audit of laboratory practice conformance with guidelines for antiphospholipid tests | Sophie Moores | ![]() |
![]() |
|||
133-PO | Real-World Data for the Efficacy and Safety of Acalabrutinib Across Two Centres in East England | Edward Benn | ![]() |
![]() |
|||
134-EP | Hyperhomocysteinemia-associated Thrombosis in Patients With Pernicious Anemia | Thura Htut | ![]() |
![]() |
|||
135-EP | An Audit to Assess Venous Thromboembolism Prevention Management in Pregnant/Postpartum Hospital Inpatients | Clarissa Pui | ![]() |
![]() |
|||
136-EP | An Audit to Assess Venous Thromboembolism Prevention Management for COVID-19 Positive Hospital Inpatients | Clarissa Pui | ![]() |
![]() |
|||
137-EP | A Review of Hospital-Associated Thrombosis with a Shared Learning Dashboard | Clarissa Pui | ![]() |
![]() |
|||
138-EP | Von Willebrands disease and gastrointestinal angiodysplasia: a case series from a haemostasis and thrombosis centre | Chloe Merrion | ![]() |
![]() |
|||
139-EP | Root Cause Analyses of Deaths Associated with Hospital-Acquired Venous Thromboses Over Twelve Months | Kaysar Mohammadi | ![]() |
![]() |
|||
140-EP | Evaluation of D-dimer Cut-Off Levels for VTE Diagnosis in a Tertiary Centre | Ala Bawazir | ![]() |
![]() |
|||
140-PO | Final Results: Phase 1b Study of Subcutaneous Isatuximab Administration by OBDS Plus Pomalidomide-dexamethasone in RRMM | Nicholas Burnley-Hall | ![]() |
![]() |
|||
141-PO | 30-Minute Infusion of Isatuximab in Newly Diagnosed Multiple Myeloma Patients: Results of Phase 1b Study | Sheetal Fermahan | ![]() |
![]() |
|||
141-EP | Time-in-Therapeutic Range (TTR) falls as the INR range increases in patients on warfarin | Imran Malik | ![]() |
![]() |
|||
142-EP | Variation of monitoring for Vitamin K antagonist in antiphospholipid syndrome (APS) | Saniya Khakwani | ![]() |
![]() |
|||
143-EP | Venous Thromboembolic Events in a Scottish District General Hospital: Variation in Management and Significant Recurrence | Philippa Stimpson | ![]() |
![]() |
|||
145-EP | Magnetic Nanoparticles: the Possibility of Applications in the Technology of Purification of Factor VIII Coagulation | Nataliya Shurko | ![]() |
![]() |
|||
146-EP | Audit of Comprehensive Care of Haemophilia B against World Federation of Haemophilia Guidelines. | Jayna Mistry | ![]() |
![]() |
|||
147-EP | Antiphospholipid Syndrome Vasculopathy with Severe Aortic Stenosis | Dina Osman | ![]() |
![]() |
|||
148-PO | Single-Cell Multi-Omic Correlation of SNVs, CNV and Surface Epitopes for Clonal Profiling of Myeloma | Matteo Cattaneo | ![]() |
![]() |
|||
148-EP | Investigating The Utility and Clinical relevance of Thrombin Time | Rishabh Motiwale | ![]() |
![]() |
|||
149-EP | Managing Pelvic Intraperitoneal Bleed Secondary to Ovulation in Adolescents with Congenital Bleeding Disorders. | Pallav Rakesh | ![]() |
![]() |
|||
151-PO | Pirtobrutinib and Venetoclax Rituximab in Relapsed/Refractory Chronic Lymphocytic Leukemia: Updated BRUIN Phase 1b Results | Huseini Kagdi | ![]() |
![]() |
|||
152-EP | Cost-efficiency of home treatment/early discharge low risk patients with pulmonary embolism in a low-income country | Galina Sorici | ![]() |
![]() |
|||
153-EP | Healthcare Resource Utilisation of Patients with VWD Treated with Recombinant Von Willebrand Factor: Chart Review | Ollie Heard | ![]() |
![]() |
|||
154-EP | A 13-month Audit on Adherenceand Outcomes of Bridging Therapy at a UK Tertiary Centre | Hassan Mahfouz | ![]() |
![]() |
|||
155-EP | The consequences of delayed diagnosis of pulmonary embolism, a comparative study | Nadejda Diaconu | ![]() |
![]() |
|||
156-EP | Prospective Data Collection Project to Facilitate Audit in the Nurse-Led DVT Service | Rebecca Cloudsdale | ![]() |
![]() |
|||
157-EP | VTE associated with N2O Use: No Laughing Matter | Aizzah Mahmood | ![]() |
![]() |
|||
158-EP | Evaluation Astrazanica Vaccine of COVID-19 on PT, APTT Among Sudanese Vaccinated | Abdelrahim Sara | ![]() |
![]() |
|||
159-EP | Comparison between CMV viraemia in Fully Matched and Haploidentical Stem Cell Transplants in Acute Leukaemia. | Asmaa Mohsen | ![]() |
![]() |
|||
160-EP | Utility of PBSC collection post salvage chemotherapy for relapsed and refractory lymphomas-A single centre study | Nkemdirim Ernest Jacob | ![]() |
![]() |
|||
161-EP | EARLY CRS PREDICTING ICANS AND ACUTE INFECTIONS PREDICTING PROGRESSION IN DLBCL PATIENTS RECEIVING CAR-T THERAPY | Khalil Begg | ![]() |
![]() |
|||
162-EP | Integration of palliative care with CAR T services a first year experience | Maimoona Ali | ![]() |
![]() |
|||
163-EP | Positive Complement Dependent Cytotoxicity Crossmatch following Covid 19 Vaccination in a Patient awaiting Renal Transplantation | Induni Gallage | ![]() |
![]() |
|||
164-EP | Evaluation of Apheresis Parameters for Optimal Autologous Peripheral Blood Stem Cell Harvesting from Lymphoma Patients | Dilupa Gunasekara | ![]() |
![]() |
|||
165-EP | Characteristics, prognostic indicators and survival Among Omani Patients Diagnosed With Chronic Lymphoid Leukemia at SQUH | Salim Al Ruqeishi | ![]() |
![]() |
|||
166-EP | Rituximab Prior To Venetoclax Is Safe And Effective In Relapsed/Refractory Chronic Lymphocytic Leukemia | Peter Johnstone | ![]() |
![]() |
|||
167-EP | A Retrospective Review of SPEP Testing Practices and MGUS diagnosis in a Community Hospital | Chun Siu | ![]() |
![]() |
|||
168-EP | Diagnostics and treatment in AL Amyloidosis with Cardiac Involvement- A Dual Centre Retrospective Cohort Study | Ewan Evans | ![]() |
![]() |
|||
169-EP | Investigating Infection in Multiple Myeloma Patients on Anti-CD38 Monoclonal Antibody Treatment | Hannah Furness | ![]() |
![]() |
|||
170-EP | Triple Class Refractory Patient and Carer Experience of Living with Multiple Myeloma | Noreen Ali | ![]() |
![]() |
|||
172-EP | Switching From Covalent BTKi to BCL2i Improves Outcomes Versus Using a Sequential BTKi in CLL/SLL | bernadette lazar | ![]() |
![]() |
|||
173-EP | Venetoclax; Implementation of Out-Patient Monitoring | Tracey Arthur | ![]() |
![]() |
|||
174-EP | Beyond Hospital Doors- Bringing Cancer Treatment to the patients own home; The Rotherham Experience | Suhani Ghiya | ![]() |
![]() |
|||
175-EP | A snapshot of UK clinical trial activity in myeloma: reflections on recruitment and patient experience | Rhys Owens | ![]() |
![]() |
|||
176-EP | Management of Monoclonal Gammopathy of Undetermined Significance Patient Group, by Haematology Advanced Nurse Practitioners. | Katharine Hanlon | ![]() |
![]() |
|||
177-EP | Real World Characteristics and Outcomes for Triple Class Exposed Myeloma Patients on Pomalidomide and Dexamethasone | Carmen Tsang | ![]() |
![]() |
|||
178-EP | Characteristics of Newly Diagnosed Myeloma Patients With and Without Transplant: Real-world Big Data From England | Sheetal Fermahan | ![]() |
![]() |
|||
179-EP | A matching-adjusted indirect comparison of ELEVATE-TN versus SEQUOIA: in treatment-naïve chronic lymphocytic leukemia. | Miguel Miranda | ![]() |
![]() |
|||
180-EP | Real-World Outcomes of Triple-Class Exposed Patients with Relapsed Multiple Myeloma in England: Follow-up Analysis | Annie LIED-LIED | ![]() |
![]() |
|||
181-EP | Multiple Myeloma with Central Nervous System Disease: Three Cases From Nottingham City Hospital | Jennifer Ryan | ![]() |
![]() |
|||
182-EP | Paraneoplastic Granulocyte Colony-Stimulating Factor Secretion in a Patient with Multiple Myeloma - A Case Report. | Rebekah Picken | ![]() |
![]() |
|||
183-EP | Audit of thromboprophylaxis prescription in multiple myeloma patients receiving immunomodulatory-drug therapy | Niharika Manu | ![]() |
![]() |
|||
184-EP | Incidentalomas in patients with multiple myeloma, MGUS, and plasmacytomas - results of 150 PET-CTs | Catherine Chinnery | ![]() |
![]() |
|||
185-EP | Teclistamab Monotherapy First Experience in Patient with Refractory Multiple Myeloma in Russia | Stanislav Kamyshanov | ![]() |
![]() |
|||
186-EP | Newly Diagnosed Multiple Myeloma VRD Protocol Treatment Precursory Results | Arman Arakelyan | ![]() |
![]() |
|||
187-EP | Venetoclax Obinutuzumab for Chronic Lymphocytic Leukaemia: Is stringent TLS monitoring proportional to risk? | Thomas Mayo | ![]() |
![]() |
|||
188-EP | EPIC: A Non-Interventional Cohort Study of Patients with Chronic Lymphocytic Leukaemia Treated with First-Line Acalabrutinib | Renata Walewska | ![]() |
![]() |
|||
189-EP | Experience of the use of Belantamab Mafodotin in a UK Teaching Hospital | Aritri Mandal | ![]() |
![]() |
|||
190-EP | Venetoclax Effectiveness After Bruton Tyrosine Kinase Inhibitors In Chronic Lymphocytic Leukaemia: An International Real-World Study | bernadette lazar | ![]() |
![]() |
|||
191-EP | Myeloma masquerading as Myeloproliferative Neoplasm (MPN) A Case Report | Katarina Flatman | ![]() |
![]() |
|||
192-EP | Single-centre outcomes for high and ultra-high risk myeloma patients since the introduction of lenalidomide maintenance | Jennifer Ryan | ![]() |
![]() |
|||
193-EP | Pirtobrutinib in Post-cBTKi CLL/SLL With/Without Prior BCL2i: Phase 1/2 BRUIN Study 30 Months Follow-Up Analysis | Huseini Kagdi | ![]() |
![]() |
|||
194-EP | Genomic Evolution/Resistance during Pirtobrutinib therapy in Covalent BTK-Inhibitor (cBTKi) Pre-treated Chronic Lymphocytic Leukemia Patients (Update) | Huseini Kagdi | ![]() |
![]() |
|||
196-EP | Assigning Disease Risk in New Multiple Myeloma: Improving Practice to Prepare for Risk-Adaptive Treatment Strategies | Amalachukwu Nwosu | ![]() |
![]() |
|||
197-EP | Impact of Obesity on Melphalan Dosing in Myeloma Patients undergoing Autologous Stem Cell Transplantation. | Imogen Welding | ![]() |
![]() |
|||
198-EP | Real-World Experience of Implementation of Quadruplet Chemotherapy for Myeloma Patients in an NHS Cancer Centre. | Salam Youssef | ![]() |
![]() |
|||
199-EP | Initial findings from a first-in-human Phase 1a/b trial of NX-5948, a ive BTK degrader | Lee Miller | ![]() |
![]() |
|||
200-EP | Targeted Use of RNA Fusion Panels in the Diagnostic Work-Up of Selected Haematological Malignancies | Oliver Firth | ![]() |
![]() |
|||
201-EP | Is It A Major Or Minor Problem? Transfusion Errors In Haemopoietic Stem Cell Transplants 2011-2022 | Victoria Tuckley | ![]() |
![]() |
28-30 April Liverpool
![]() |
Digital Object Identifier. Official code used to identify documents published on internet; similar to ISBN for books. You may use this code to reference your poster in future scientific publications or CVs. It can be found from anywhere in the world. ![]() To find the poster page, log onto www.medra.org and enter the DOI, or enter in your internet browser https://dx.doi.org/ followed by the DOI string asigned to your congress. ![]() |
![]() |
||
![]() |
|